Going-concern and financing shortfall
The company states cash may not be sufficient and expects to raise additional equity.
- Scope
- Pre-revenue operations and ongoing R&D funding
- Materiality
- high
Genvor Inc
Genvor Inc. is a U.S.-based agricultural biotechnology company developing antimicrobial peptide technologies for crop protection and trait enhancement. Its platform is aimed at replacing or reducing conventional chemical pesticides through non-GMO biological sprays and seed-trait applications, with additional research into animal health and nutrition uses.
0.03
0.03
| % | |
|---|---|
| Crop protection peptides | 45% Peptide-based solutions designed to control bacterial, fungal, and viral plant diseases. |
| Seed traits | 20% Transgenic or trait-based crop applications intended to improve resistance and performance. |
| Biological sprays | 15% Residue-free spray formulations for conventional and organic crop protection use. |
| Animal health and nutrition | 10% Peptide applications under development for poultry, swine, and aquaculture feed systems. |
| Licensing and collaborations | 10% Partner-led commercialization, research agreements, and royalty-style monetization. |
Genvor’s direct customers are likely to be agricultural companies, seed and crop-input partners, and research...
- Agricultural licensing partnersprimary
Companies that license Genvor's peptide technologies for commercialization and distribution.
- Crop protection and seed companiesprimary
Buy or co-develop biological sprays and seed traits to improve disease resistance and crop performance.
- Public research institutionssecondary
USDA and similar bodies support CRADA-based R&D to reduce development cost and speed validation.
- Animal health and feed partnersemerging
Collaborators exploring peptide applications for poultry, swine, and aquaculture nutrition.
Genvor is headquartered in the United States and operates an R&D laboratory in Woodland, California...
- •United States is the core operating base and likely first commercialization market
- •Woodland, California lab supports R&D and partner collaboration
- •USDA CRADA work anchors development in U.S. public research infrastructure
- •Bayer-supported AgStart access improves U.S. innovation and validation capacity
- •Global commercialization is expected to come through licensing partners
Genvor is pursuing a capital-light strategy built around third-party research, licensing, and collaborative development...
01
Advance peptide-based crop protection productsshort-term
Core platform must prove efficacy and regulatory fit before licensing can scale.
02
Expand CRADA and partner-led R&Dshort-term
External research lowers capital needs and speeds development with established infrastructure.
03
Commercialize through licensing and royaltiesmedium-term
The company lacks scale manufacturing and marketing capacity, so partner monetization is essential.
04
Broaden platform into animal health and nutritionmedium-term
Cross-sector use cases can diversify revenue and reuse the same peptide discovery engine.
Genvor remains a pre-revenue development company, so its biggest risk is funding: it may not raise enough capital to...
Regulatory and compliance delays
Agricultural biologicals and seed traits require approvals and can face changing rules.
- Scope
- Crop protection, seed traits, and animal health applications
- Materiality
- high
Dependence on third-party partners
The licensing-first model needs USDA, Bayer, and future partners to validate and commercialize.
- Scope
- CRADAs, licensing, distribution, and market access
- Materiality
- high
Technology and adoption risk
Peptide products must prove efficacy, durability, and cost-effectiveness versus incumbents.
- Scope
- Crop disease control and residue-free agriculture markets
- Materiality
- high
Personnel concentration
The company has only a few employees and relies on advisors and contractors.
- Scope
- R&D continuity and commercialization execution
- Materiality
- medium
Stock-based compensation
Can materially increase operating expenses and dilute shareholders
Deferred tax asset valuation allowance
Can change net income and balance-sheet tax asset values
Going-concern assessment
Affects disclosure, liquidity analysis, and financial statement interpretation
Non-cash equity issuances
Impacts expense recognition, equity balances, and dilution
Ginkgo Bioworks Holdings, Inc.
DNA · Biological Products, (No Diagnostic Substances)
Xencor Inc
XNCR · Pharmaceutical Preparations
BURZYNSKI RESEARCH INSTITUTE INC
BZYR · In Vitro & In Vivo Diagnostic Substances
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
NEOGEN CORP
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
NANOVIRICIDES, INC.
NNVC · Pharmaceutical Preparations
: 28/04/2026